Technical outcomes of sentinel-lymph node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: Results from the NSABP
B-32 randomized phase-III trial.
In the adjuvant phase III NSABP
B-31 trial, PAM50 failed to identify subgroups that benefited differentially from trastuzumab , whereas in the NCCTG-N9831 trial, patients with HER2-E or luminal tumors benefited from the addition of trastuzumab to chemotherapy, unlike those with basal-like tumors , suggesting the need to further evaluate this predictor in the adjuvant setting.
Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP
B-17 and B-24 Randomized Clinical Trials for DCIS.
Paik et al., "Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP
protocol B-24," Journal of Clinical Oncology, vol.
Sentinel lymph node resection compared with conventional axillary lymph node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP
B-32 randomised phase 3 trial.
[5,6] The biggest trial comparing preoperative vs post-operative CT is NSABP
18 in which 1523 patients with operative Breast cancer were randomized to preop doxorubicin and cyclophosphamide (AC) vs postop (AC) and demonstrated equal efficacy in NACT & postop CT group while NACT allowed more Breast conservation therapy and concluded that although there is no survival benefit there is no disadvantage from use of NACT.
Neither the NSABP
B-24 nor the UK, Australia, and New Zealand studies showed any increase in other causes of mortality with the use of tamoxifen (33, 34).
Moreover, the 16.5% 4year rate of IBTR is higher than the 8-year IBTR rate of 13.4% seen in ER negative patients treated with WBI in the absence of adjuvant chemotherapy in the National Surgical Adjuvant Bowel and Breast project (NSABP
) B-13 study .
Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP
) eight-year update of Protocol B-17: intraductal carcinoma.
The oft-cited figure of a 50% reduction in breast cancer risk conferred by tamoxifen comes from the landmark randomized, placebo-controlled NSABP
(National Surgical Adjuvant Breast and Bowel Project) P-1 trial U.